Geode Capital Management LLC Has $37.58 Million Position in Xencor, Inc. (NASDAQ:XNCR)

Geode Capital Management LLC increased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 12.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,634,876 shares of the biopharmaceutical company's stock after acquiring an additional 179,526 shares during the quarter. Geode Capital Management LLC owned about 2.34% of Xencor worth $37,578,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Sanctuary Advisors LLC bought a new position in shares of Xencor during the third quarter worth $540,000. Barclays PLC grew its stake in Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after acquiring an additional 78,066 shares during the period. Prudential Financial Inc. increased its holdings in shares of Xencor by 10.7% in the fourth quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company's stock worth $1,625,000 after acquiring an additional 6,810 shares in the last quarter. Jane Street Group LLC raised its position in shares of Xencor by 18.6% during the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock worth $3,387,000 after purchasing an additional 26,473 shares during the period. Finally, Wellington Management Group LLP acquired a new position in shares of Xencor in the 4th quarter valued at approximately $632,000.

Analysts Set New Price Targets

A number of brokerages have weighed in on XNCR. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $33.86.

Xencor Stock Up 1.9 %

Shares of NASDAQ:XNCR traded up $0.18 during midday trading on Friday, reaching $9.70. The company had a trading volume of 614,275 shares, compared to its average volume of 622,036. The business's 50 day moving average price is $12.33 and its 200 day moving average price is $18.72. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $683.48 million, a PE ratio of -3.03 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million for the quarter, compared to analysts' expectations of $17.14 million. Research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.